According to the press release, preliminary results show substantial reductions in left ventricular outflow tract gradients (LVOT), with only modest decreases in left ventricular ejection fraction. (LVEF).
Based on this early positive data, the study will continue and will enroll a second group of approximately 18 patients.
Cytokinetics hopes to have results from REDWOOD-HCM in the middle of 2021, and hopes to begin a Phase 3 trial for CK-274 by the end of 2021.
For detailed information about this trial see ClinicalTrials.gov.